http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#Head
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#provenance
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#pubInfo
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion
http://www.w3.org/ns/prov#wasGeneratedBy
S&T TWOC project version 1
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#version
http://www.w3.org/ns/prov#value
1
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C0013227
drugs
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C0021764
interleukin
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C0245109
anakinra
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C1299393
moderate to severe
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C1513853
non
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C1527200
interleukin
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C1533148
cases
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C1609165
tocilizumab
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C1609931
siltuximab
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
https://uts.nlm.nih.gov/uts/umls/concept/C3687832
drugs
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
http://twoc-nlp-database-server-1:8555/solr/predicates/select?q=TRIPLE_UID:pq34mfzt-TRIPLE-ABSTRACT-2
be
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C0011777
dexamethasone
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C0178602
dose
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C0205251
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C0869039
dose
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C1550472
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C1611820
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C1619811
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C2700150
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C3890211
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C4048187
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C4321351
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C4522223
low
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://uts.nlm.nih.gov/uts/umls/concept/C5203106
low
http://www.w3.org/2000/01/rdf-schema#Triple-UID
http://twoc-nlp-database-server-1:8555/solr/triples/select?q=TRIPLE_UID:pq34mfzt-TRIPLE-ABSTRACT-2
pq34mfzt-TRIPLE-ABSTRACT-2
http://www.w3.org/2000/01/rdf-schema#sentence
http://www.w3.org/2000/01/rdf-schema#label
To target the inflammatory cascade, low-dose dexamethasone appears to be helpful in moderate to severe cases and trials with anti-interleukin agents (e.g., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results.
http://www.w3.org/2000/01/rdf-schema#triple
http://www.w3.org/2000/01/rdf-schema#label
low - dose dexamethasone be in moderate to severe cases and trials with anti - interleukin agents ( e.g. , tocilizumab , anakinra , siltuximab ) and non - steroidal anti - inflammatory drugs
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#provenance
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion
http://www.w3.org/ns/prov#generatedAtTime
2021-07-25T21:46:20.879852
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#pubInfo
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig
http://purl.org/nanopub/x/hasSignature
ZappbXqFom74kzqytuyy81GX87uQV1IZTWGtOc/KNsnEuF/H7ivtcu4vMTEa7vZACiqOQR+4JR/r+p7kUEfFWvfKuITyKbNp9unIQVcxtJWtoig6qr1YBejcDjHN9Wc0fHh0uDndYwgq6QM+Z+B1uwZ8z+U4eyHRdWmNau3VZmA=
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://www.w3.org/ns/prov#generatedAtTime
2021-07-25T21:46:20.879852
http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-8954-0470